Clinical outcomes in patients with implantable cardioverter defibrillators and Sprint Fidelis leads. Issue 11 (22nd February 2013)

• Record Type: Journal Article
• Authors: Verlato, Roberto; Facchin, Domenico; Catanzariti, Domenico; Molon, Giulio; Zanotto, Gabriele; Morani, Giovanni; Brieda, Marco; Zanon, Francesco; Delise, Pietro; Leoni, Loira; Comisso, Jennifer; Campo, Claudia
• Is Part Of: Heart. Volume 99:Issue 11(2013)
• Page Start: 799
• Page End: 804
• Publication Date: 2013-02-22
• Subjects: Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heartjnl-2012-303259
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Objective: The performances of implantable cardioverter defibrillators and leads are important issues for healthcare providers and patients. In 2007 Sprint Fidelis leads were found to be associated with an increased failure rate and so the purpose of the study was to evaluate long-term mortality and clinical outcomes in patients implanted with Sprint Fidelis leads compared with Sprint Quattro leads. Design, setting, patients: 508 patients with Sprint Fidelis leads and 468 with Sprint Quattro leads were prospectively followed in 12 Italian cardiology centres. Main outcome measures: Information on hospitalisations and other clinical events were collected during scheduled and unscheduled hospital visits. Deaths were identified from medical records or via phone contacts with patients' family members or through the National Office of Vital Statistics. Results: Over a mean follow-up of 27±18 months 141 deaths occurred in the overall population. No death was observed in patients with diagnosed failing lead. Kaplan-Meier patient survival differed between the two lead groups (80±2% in Fidelis leads vs 70±4% in the Sprint Quattro leads at 4 years, p=0.002). Multivariate analyses showed that mortality was neither associated with lead type nor with diagnosed failed lead. The annual rate of lead failure was 1.8% patient-year for Fidelis leads and 0.2% for the Sprint Quattro leads. Conclusions: In our multicentre research, the clinical outcomes of patients with Fidelis leads differed from those of patients with Sprint Quattro leads. Nevertheless, neither mortality nor the combined endpoint of mortality and heart failure hospitalisations was associated with the lead type. http://clinicaltrials.gov/ct2/show/NCT01007474 .